Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Events

Stock Quote

Change
Volume
52 Week High
52 Week Low

Copyright Nasdaq. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2018 Results
Revenue increased 203% compared to the three-month period in the prior year            Call scheduled for today, May 10 , at 4:30 pm ET TUCSON, Ariz. , May 10, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a provider of instruments, reagents and services for
Toggle Summary HTG Molecular Diagnostics to Feature Its HTG EdgeSeq Precision Immuno-Oncology Panel at Booth #4113 at the American Society of Clinical Oncology (ASCO) Conference in June 2018
The Panel will be available to researchers as part of an early access program TUCSON, Ariz. , May 10, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will
Toggle Summary HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic and Research Products and Services Based on HTG EdgeSeq Technology
TUCSON, Ariz. and HUNINGUE, France , May 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based
Toggle Summary HTG Molecular Diagnostics to Announce First Quarter Financial Results and Host Conference Call on Thursday, May 10
TUCSON, Ariz. , April 27, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter ended March 31, 2018 after the market
Toggle Summary HTG Promotes John Lubniewski to President and Chief Operating Officer
Mr. Lubniewski assumes the role after having served for seven years as Chief Business Officer TUCSON, Ariz. , April 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the

Stock Chart

SEC Filings

Filing date Description

CT ORDER

Official notification to shareholders of matters to be brought to a vote ("Proxy")

Additional proxy soliciting materials - definitive

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities